Xortx Therapeutics Inc (XRTX) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Xortx Therapeutics inc   (NASDAQ: XRTX)


Xortx Therapeutics Inc's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Xortx Therapeutics Inc's ROI in the fourth quarter of 2025?


Within the Healthcare sector Xortx Therapeutics inc achieved the highest return on investment. While the total ranking for ROI remained the same, compared to the third quarter of 2025 at no. .

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM -34.46 % -5.22 % 46.53 % 163.15 % 671.04 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 3 3 3 3 4
Return On Investment (TTM) 0 % -109.13 % -97.77 % -88.55 % -80.92 %
XRTX's Overall Ranking # # # # #
Seq. Investment Change TTM -11.62 % -10.41 % -9.43 % -8.62 % 27.81 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions 0 -3 -3 -3 -3

XRTX Company Profile >> Back to XRTX Roi Comparisons >> See Annual XRTX Return On Investment



Return On Investment XRTX's Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Investment Statistics
High Average Low
0 %
0 %
0 %
 



  News about Xortx Therapeutics inc Return on Investment ROI

XORTX Appoints Dr. Michael Bumby as CFO Amid Substantial Financial Losses and Declining ROI

December 19, 2024

XORTX Therapeutics Inc. has announced a significant addition to its executive team with the appointment of Dr. Michael Bumby as Chief Financial Officer (CFO). Dr. Bumby s expertise in the pharmaceutical and biotechnology sectors aims to bolster the firm s financial strategy as it navigates a turbulent financial landscape. However, the company has faced harsh realities, with its share price plummeting by 23.53% during the fourth quarter of 2023, reflecting concerns over its financial stability.The recent financial disclosures reveal that XORTX recorded a cumulative net loss of $2 million for the 12 months ending in Q4 2023. This staggering figure corresponds to a return on investment (ROI) of -406.39%, a striking indicator of the company s struggles compared to its peers in the healthcare sector. Out of 631 companies analyzed within the same industry, XORTX s financial performance was alarmingly subpar, highlighting an urgent need for effective financial leadership and operational turnaround.

Integrating Genetics for Precision Medicine XORTXs Innovative Path in Kidney Disease Treatment

October 9, 2024

In a significant stride towards pioneering advancements in kidney disease therapy, XORTX Therapeutics Inc. (XORTX or the Company) has announced the initiation of its Precision Medicine Program. This program leverages innovative research focused on the genetic regulation of xanthine oxidase and aims to offer therapeutic solutions targeting aberrant purine metabolism. This development marks a transformative phase in XORTX s mission to combat progressive kidney disease, reflecting the company s dedication to precision and personalized medicine. Alongside the launch of this ambitious program, XORTX has outlined its considerable achievements from 2023 and set forward-looking s for 2024, indicating a robust pathway towards their next clinical trial phase. Exploration of Genetic Regulation and Therapeutic Targeting At the core of XORTX s new initiative is groundbreaking research that investigates the genetic factors influencing the activity of xanthine oxidase. Xanthine oxidase is a critical enzyme involved in purine metabolism, and its dysregulation is associated with multiple pathological states, including hyperuricemia, gout, and chronic kidney disease. By understanding the genetic determinants that govern xanthine oxidase activity, XORTX seeks to develop precision medicine approaches that could lead to more effective and individualized treatment regimens.





Financial Statements
Xortx Therapeutics Inc's IV. Quarter Investments $ 3 Millions XRTX's Balance sheet
Xortx Therapeutics Inc's IV. Quarter Income $ 0 Millions Quarterly XRTX's Income Statement
XRTX's Income by Division See XRTX's Income by Division


XRTX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2021)
2021
Total Investments in Millions 1 1 1 17 0
Y / Y Investment Growth -20.97 % 42.74 % -96.81 % - -
Net Income in Millions 0 -3 -2 -1 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment 0 % -437.12 % -406.39 % -7.93 % -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
XRTX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for XRTX's Competitors
Subscribers only: Roi for Xortx Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for XRTX's Customers

Other Ratios
XRTX's Roa XRTX's Inventory Turnover Ratio XRTX's Growth Rates XRTX's Dividend Statistics
XRTX's Profitability Ratios XRTX's Asset Turnover Ratio XRTX's Dividend Growth
XRTX's Roe XRTX's Valuation Ratios XRTX's Financial Strength Ratios XRTX's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.